Pertuzumab –Cancer Therapy
Key Data:
Drug (brand/generic)
Pertuzumab
Company/licensee
Roche/Genentech
Therapy class
HER dimerisation inhibitor (HDI)
Product description
Inhibits dimerisation of the HER2 protein with other members of the HER family of receptors
Current indication
Breast cancer
Market sector
Oncology
Development status
Phase III
